Clinical Trials Logo

Elevated Cholesterol clinical trials

View clinical trials related to Elevated Cholesterol.

Filter by:

NCT ID: NCT05091073 Completed - Healthy Volunteers Clinical Trials

A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants

Start date: December 9, 2021
Phase: Phase 1
Study type: Interventional

In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood. The dose to be tested in this study is 40 mg NNC0385-0434. NNC0385-0434 is a new potential medicine that is currently being tested for intake as a tablet. It is not yet approved and cannot be prescribed yet. Besides 40 mg of NNC0385-0434, each tablet also contains 500 mg of the absorption enhancing agent SNAC, which helps to move NNC0385-0434 from the stomach into the blood. The aim of this study is to investigate the effect of food intake on the amount of NNC0385-0434 in the blood after multiple tablet intake. For this purpose, NNC0385-0434 is given either after a high-fat breakfast or on an empty stomach. After dosing, participants must either fast for another 4 hours or receive a meal 30 minutes after dosing, depending on the group participants are assigned to. After taking the NNC0385-0434 tablets, the amount of NNC0385-0434 (and of SNAC) in the blood will be measured. The effect of food intake on the uptake of NNC0385-0434 into the body will be investigated so that correct and safe intake recommendations and medicine labels can be given. The study can last for up to approximately 14 weeks for each participant, with a total of 7 clinic visits. This includes a screening period (up to 4 weeks) and one in-house treatment period (together a total of 13 consecutive days). It also includes a follow-up period with 5 ambulatory visits at the clinic (for approximately 7 weeks [total of 50 days] after the last dosing). participants will have blood tests at every clinic visit. Participants must be healthy and have a body mass index (BMI) between 20.0 and 34.9 kg/m2 (both inclusive). Only men can participate in this clinical study.

NCT ID: NCT04798430 Enrolling by invitation - Clinical trials for Familial Hypercholesterolemia

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

LIBerate-OLE
Start date: December 3, 2020
Phase: Phase 3
Study type: Interventional

The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W [<31 days]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.

NCT ID: NCT04148339 Recruiting - Clinical trials for Elevated Cholesterol

A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Elevated Cholesterol.

NCT ID: NCT03814187 Completed - Clinical trials for Homozygous Familial Hypercholesterolemia

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

ORION-8
Start date: April 16, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.

NCT ID: NCT03400800 Completed - Clinical trials for Risk Factor, Cardiovascular

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

ORION-11
Start date: November 1, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be an international multicenter study (non-United States).

NCT ID: NCT03399370 Completed - ASCVD Clinical Trials

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

ORION-10
Start date: December 21, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.

NCT ID: NCT03397121 Completed - Clinical trials for Heterozygous Familial Hypercholesterolemia

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

ORION-9
Start date: November 28, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase III, placebo-controlled, double-blind, randomized study in participants with HeFH and elevated LDL-C to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) injection(s) of inclisiran. The study will be multicenter and international.

NCT ID: NCT03134235 Completed - Hypertension Clinical Trials

Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors

Start date: January 3, 2017
Phase: N/A
Study type: Interventional

This study evaluates the effects of a prescribed 4-week raw, plant-based dietary intervention in the treatment of excess body weight, hypercholesterolemia, and hypertension in the clinical setting.

NCT ID: NCT02990637 Completed - Clinical trials for Overweight and Obesity

The Effect of Olive Leaf Extract Administration on Cardiovascular Health

Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of daily supplementation of OLECOL for a period of 8 weeks on cardiovascular risk markers.

NCT ID: NCT01702883 Active, not recruiting - Hypertension Clinical Trials

The Medication Experience Study

Start date: October 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve medication use.